Combining longitudinal studies of PSA

Biostatistics

Volumn 5, Issue 3, 2004, Pages 483-500

  Inoue, Lurdes Y T ^a,b   Etzioni, Ruth ^b   Slate, Elizabeth H ^c   Morrell, Christopher ^d   Penson, David F ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d LOYOLA UNIVERSITY MARYLAND   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bayesian hierarchical model; Interval censored data; Longitudinal data; Meta analysis; Prostate specific antigen (PSA)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BAYES THEOREM; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; HUMAN; LONGITUDINAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; PROSTATE TUMOR; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; BAYES THEOREM; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 21644490251     PISSN: 14654644     EISSN: None     Source Type: Journal    
DOI: 10.1093/biostatistics/kxh003     Document Type: Article

References (49)

1. BLUTE, M. L., BERGSTRALH, E. J., PARTIN, A. W., WALSH, P. C., KATTAN, M. W., SCARDINO, P. T., MONTIE, J. E., PEARSON, J. D., SLEZAK, J. M. AND ZINCKE, H. (2000). Validation of partin tables for predicting pathological stage of clinically localized prostate cancer. Journal of Urology 164, 1591-1595.
2. BOOTH, N. B. AND SMITH, A. F. M. (1982). A Bayesian approach to retrospective identification of change-points. Journal of Econometrics 19, 7-22.
3. BRANT, L. J., SHENG, S. L., MORRELL, C. H., VERBEKE, G. N., LESAFFRE, E. AND CARTER, H. B. (2003). Screening for prostate cancer using random-effects models. Journal of Royal Statistical Society: Series A 166, 51-62.
4. BRAWER, M. K., BANKSON, D. D., HAVER, V. M. AND PETTEWAY, J. C. (1997). Comparison of three commercial PSA assays: results of restandardization of the Ciba Corning method. The Prostate 30, 269-273.
5. CARLIN, B. P., GELFAND, A. E. AND SMITH, A. F. M. (1992). Hierarchical Bayesian analysis of changepoint-problems. Applied Statistics 41, 389-405.
6. CARTER, H. B., PEARSON, J. D., METTER, E. J., BRANT, L. J., CHAN, D. W., ANDRES, R., FOZARD, J. L. AND WALSH, P. C. (1992a). Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. Journal of the American Medical Association 267, 2215-2220.
7. CARTER, H. B., MORRELL, C. H., PEARSON, J. D., BRANT, L. J., PLATO, C. C., METTER, E. J., CHAN, D. W., FOZARD, J. L. AND WALSH, P. C. (1992b). Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Research 52, 2232-3328.
8. CARTER, H. B., EPSTEIN, J. I., CHAN, D. W., FOZARD, J. L. AND PEARSON, J. D. (1997). Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. Journal of the American Medical Association 277, 1456-1460.
9. CLARK, L. C., COMBS, G. F., TURNBULL, B. W., SLATE, E. H., CHALKER, D. K., CHOW, J., DAVIS, L., GLOVER, R. A., GRAHAM, G. F., GROSS, E. G., KRONGRAD, A., LESHER, J. L., PARK, H. K., SANDERS, B. B., SMITH, C. L. AND TAYLOR, J. R. (1996). Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Journal of the American Medical Association 276, 1957-1963.
10. DRAISMA, G., BOER, R., OTTO, S. J., VAN DER CRUIJSEN, I. W., DAMHUIS, R. A., SCHRODER, F. H. AND DE KONING, H. J. (2003). Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. Journal of the National Cancer Institute 95, 868-878.
11. DUFFIELD-LILLICO, A. J., SLATE, E. H., REID, M. E., TURNBULL, B. W., WlLKINS, P. A., COMBS, G. F., PARK, H. K., GROSS, E. G., GRAHAM, G. F., STRATTON, M. S., MARSHALL, J. R. AND CLARK, L. C. (2003). Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. Journal of the National Cancer Institute 95, 1477-1481.
12. DUMOUCHEL, W. H. AND HARRIS, J. E. (1983). Bayes methods for combining the results of cancer studies in humans and other species with discussion. Journal of the American Statistical Association 78, 293-315.
13. EASTHAM, J. A., RIEDEL, E., SCARDINO, P. T., SHIKE, M., FLEISHER, M., SCHATZKIN, A., LANZA, E., LATKANY, L. AND BEGG, C. B. (2003). Variation of serum prostate-specific antigen levels - an evaluation of year-to-year fluctuations. Journal of the American Medical Association 289, 2695-2700.
14. ELLIS, W. J., ETZIONI, R., VESSELLA, R. L., HU, C. AND GOODMAN, G. E. (2001). Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. Journal of Urology 166, 93-98,. discussion 98-99.
15. ETZIONI, R., CHA, R. AND COWEN, M. E. (1999). Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. Journal of Urology 162, 741-748.
16. ETZIONI, R., PENSON, D. F., LEGLER, J. M., DI TOMMASO, D., BOER, R., GANN, P. H. AND FEUER, E. J. (2002a). Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. Journal of the National Cancer Institute 94, 981-990.
17. ETZIONI, R., BERRY, K. M., LEGLER, J. M. AND SHAW, P. (2002b). Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. Urology 59, 251-255.
18. FRANKEL, S., SMITH, G. D., DONOVAN, J. AND NEAL, D. (2003). Screening for prostate cancer. The Lancet 361, 1122-1128.
19. FRYDENBERO, M., STRICKER, P. D. AND KAYE, K. W. (1997). Prostate cancer diagnosis and management. The Lancet 349, 1681-1687.
20. GELFAND, A. E. AND SMITH, A. F. M. (1990). Sampling-based approaches to calculating marginal densities. Journal of the American Medical Association 85, 398-409.
21. GEMAN, S. AND GEMAN, D. (1984). Stochastic relaxation, Gibbs distributions, and the Bayesian restoration to images. IEEE Transactions on Pattern Analysis and Machine Intelligence 6, 721-741.
22. JEMAL, A., MURRAY, T., SAMUELS, A., GHAFOOR, A., WARD, E. AND THUN, M. J. (2003). Cancer statistics, 2003. CA: A Cancer Journal for Clinicians 53, 5-26.
23. KABALIN, J. N., MCNEAL, J. E., JOHNSTONE, I. M. AND STAMEY, T. A. (1995). Serum prostate-specific antigen and the biologic progression of prostate cancer. Urology 46, 65-70.
24. KASS, R. E. AND RAFTERY, A. E. (1995). Bayes factors. Journal of the American Statistical Association 90, 773-795.
25. LEEWANSANGTONG, S., GOKTAS, S., LEPOFF, R., HOLTHAUS, K. AND CRAWFORD, E. D. (1998). Comparability of serum prostate-specific antigen measurement between the hybritech Tandem-R and Abbott AxSym Assays. Urology 52, 467-469.
26. METROPOLIS, N., ROSENBLUTH, A. W., ROSENBLUTH, M. N., TELLER, A. H. AND TELLER, E. (1953). Equations of state calculations by fast computing machine. Journal of Chemistry in Physics 21, 1087-1091.
27. MORRELL, C. H., PEARSON, J. D., CARTER, H. B. AND BRANT, L. J. (1995). Estimating unknown transition times using a piecewise nonlinear mixed-effects model in men with prostate cancer. Journal of the American Statistical Association 90, 45-53.
28. OESTERLING, J. E., JACOBSEN, S. J., CHUTE, C. G., GUESS, H. A., GIRMAN, C. J., PANSER, L. A. AND LIEBER, M. M. (1993). Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. Journal of the American Medical Association 270, 860-864.
29. OESTERLING, J. E., MOYAD, M. A., WRIGHT, G. L. AND BECK, G. R. (1995). An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E and IMx. Urology 46, 524-532.
30. PARTIN, A. W., MANGOLD, L. A., LAMM, D. M., WALSH, P. C., EPSTEIN, J. I. AND PEARSON, J. D. (2001). Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58, 843-848.
31. PARTIN, A. W., KATTAN, M. W., SUBONG, E. N. P., WALSH, P. C., WOJNO, K. J., OESTERLING, J. E., SCARDINO, P. T. AND PEARSON, J. D. (1997). Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer. Journal of the American Medical Association 277, 1445-1451.
32. PEARSON, J. D., MORRELL, C. H., LANDIS, P. K., CARTER, H. B. AND BRANT, L. J. (1994). Mixed-effects regression models for studying the natural history of prostate disease. Statistics in Medicine 13, 587-601.
33. PENSON, D. F., LITWIN, M. S. AND AARONSON, N. K. (2003). Health related quality of life in men with prostate cancer. Journal of Urology 169, 1653-1661.
34. POTOSKY, A. L., LEGLER, J., ALBERTSEN, P. C., STANFORD, J. L., GILLILAND, F. D., HAMILTON, A. S., ELEY, J. W., STEPHENSON, R. A. AND HARLAN, L. C. (2000). Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. Journal of the National Cancer Institute 92, 1582-1592.
35. POTOSKY, A. L., REEVE, B. B., CLEGG, L. X., HUFFMAN, R. M., STEPHENSON, R. A., ALBERTSEN, P. C., GILLILAND, F. D. AND STANFORD, J. L. (2002). Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. Journal of the National Cancer Institute 94, 430-437.
36. PUNGLIA, R. S., D'AMICO, A. V., CATALONA, W. J., ROEHL, K. A. AND KUNTZ, K. M. (2003). Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. The New England Journal of Medicine 349, 335-342.
37. Ross, K. S., CARTER, H. B., PEARSON, J. D. AND GUESS, H. A. (2000). Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. Journal of the American Medical Association 284, 1399-1405.
38. SHOCK, N. W., GREULICH, R. C., ANDRES, R., LAKATTA, E. G., ARENBERG, D. AND TOBIN, J. D. (1984). Normal Human Aging: The Baltimore Longitudinal Study of Aging, NIH Publication No. 84-2450. Washington, D.C.: U.S. Government Printing Office.
39. SILVERMAN, B. W. (1986). Density Estimation for Statistics and Data Analysis. London: Chapman and Hall.
40. SKATES, S. J., PAULER, D. K. AND JACOBS, I. J. (2001). Screening based on the risk of cancer calculation from Bayesian hierarchical changepoint and mixture models of longitudinal markers. Journal of the American Statistical Association 96, 429-439.
41. SLATE, E. H. AND CLARK, L. C. (1999). Using PSA to detect prostate cancer onset: an application of Bayesian retrospective and prospective change-point identification. In Case Studies in Bayesian Statistics IV, New York: Springer, pp. 511-533.
42. SLATE, E. H. AND CRONIN, K. A. (1997). Change-point modeling of longitudinal PSA as a biomarker for prostate cancer. In Case Studies in Bayesian Statistics III, New York: Springer, pp. 435-456.
43. SLATE, E. H. AND TURNBULL, B. W. (2000). Statistical models for longitudinal biomarkers of disease onset. Statistics in Medicine 19, 617-637.
44. STAMEY, T. A., YANG, N., HAY, A. R., MACNEAL, J. E., FREIHA, F. S. AND REDWINE, E. (1987). Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. New England Journal of Medcine 317, 909-916.
45. STANGL, D. K. AND BERRY, D. A. (2000). Meta-Analysis in Medicine and Health Policy. New York: Dekker.
46. STEPHENS, D. A. (1994). Bayesian retrospective multiple change-point identification. Applied Statistics 43, 159-178.
47. SULLIVAN, M. P., ETZIONI, R., FENG, Z., POTTER, J. D., THOMPSON, M. L., THORNQUIST, M., WINGET, M. AND YASUI, Y. (2001). Phases of biomarker development for early detection of cancer. Journal of the National Cancer Institute 93, 1054-1061.
48. TANNER, M. A. (1996). Tools for Statistical Inference, 3rd Edition. New York: Springer.
49. WHITTEMORE, A. S., LELE, C., FRIEDMANN, G. C., STAMEY, T., VOGELMAN, J. J. AND ORENTREICH, N. (1995). Prostate-specific antigen as predictor of prostate cancer in black man and white mean. Journal of the National Cancer Institute 87, 354-360.